12 results
Primary objective: The primary objective of the study is to determine the effect of oral dipyridamole treatment on the innate immune response induced by a lipopolysaccharide (LPS) challenge. Various pro- and anti-inflammatory cytokines will be…
The aims of the study are (1) to establish the feasibility, safety, and potential efficacy of NcAcc DBS in patients with a chronic, treatment refractory heroin and/or cocaine addiction; (2) to explore functional effects of NcAcc DBS in terms of…
To determine the best dose escalation scheme of dipyridamole added to acetylsalicylic acid, based on the side-effect headache, in patients starting secondary preventive therapy for stroke
To study whether dipyridamole reduces gastrointestinal absorption of metformin.
Explore 4 week post-treatment effect of seven day administration of dipyridamole on nucleoside transport inhibition.
1. Creating a reproducible and valid method for adenosine measurement2. Studying the effect of dipyridamole on the endogenous adenosine concentration before and after CPT.
To study the effect of oral pretreatment with dipyridamole on troponin-I release after CABG. Secondary objectives are whether oral pretreatment with dipyridamole reduces postoperative CABG arrhythmias, prolonged inotropic support, and duration of…
Creating a reproducible and valid method for adenosine measurement
The purpose of this project is to explore whether a short treatment with dipyridamole (2.5 days; i.e. 5 capsules) can reduce ischemia-reperfusion injury in the forearm.
To test the hypothesis that dipyridamole improves tolerance to ischemia-reperfusion in patients undergoing elective PCI.
The primary study objective is to evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (PE). The use of the device will be assessed…
The primary study objective is to compare the clinical outcomes of patients treated with the FlowTriever System versus Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute intermediate-high-risk pulmonary embolism (PE).